Julia D Wulfkuhle

US Patent:

20100317740, Dec 16, 2010

Filed:

Jul 28, 2008

Appl. No.:

12/669833

Inventors:

Emanuel F. Petricoin - Gainesville VA, US
Lance A. Liotta - Bethesda MD, US
Julia D. Wulfkuhle - Columbia MD, US

International Classification:

A61K 31/135
G01N 33/53
A61P 35/04

US Classification:

514648, 435 71

Abstract:

This invention relates, e.g., to a method for predicting the response of a subject having, or at risk of developing, breast cancer to Tamoxifen therapy. The method comprises measuring the amount of phosphorylation at residues S70 of Bcl-2, Y992 of EGFR, and/or Y527 of Src in a suitable sample from the subject, wherein a statistically significantly elevated level of phosphorylation at one or more of the three residues compared to a baseline value indicates that the subject is likely to be responsive to Tamoxifen therapy.

US Patent:

20110189173, Aug 4, 2011

Filed:

Jul 8, 2009

Appl. No.:

13/003206

Inventors:

Lance A. Liotta - Bethesda MD, US
Virginia Espina - Rockville MD, US
Julia D. Wulfkuhle - Columbia MD, US

Assignee:

George Mason Intellectual Properties, Inc. - Fairfax VA

International Classification:

A61K 39/395
C40B 30/00
G01N 33/574
A61K 31/517
C12Q 1/48
A61P 35/00

US Classification:

4241331, 506 7, 435 723, 51426624, 435 15

Abstract:

The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.

US Patent:

20110318336, Dec 29, 2011

Filed:

Mar 29, 2011

Appl. No.:

13/075163

Inventors:

Emanuel Petricoin, III - Gainesville VA, US
Julia Wulfkuhle - Columbia MD, US
Angela Zupa - Potenza, IT

Assignee:

George Mason Intellectual Properties, Inc. - Fairfax VA

International Classification:

A61K 39/395
A61K 31/517
A61P 35/00
A61K 31/506
A61K 31/404
C40B 40/10
C40B 30/04
A61K 31/5377

US Classification:

4241331, 506 9, 5142664, 5142345, 4241421, 51425218, 51425219, 514414, 506 18

Abstract:

This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step of determining if one or more of certain identified proteins are activated in tumor cells obtained from the patient's tumor, wherein the activation of one or more of the proteins indicates that the patient has an aggressive N0 tumor and is likely to have a poor overall-survival. The invention also provides a method for selecting a treatment for an NSCLC patient with an N0 tumor and a method for treating such patients. It further provides a kit for identifying an NSCLC patient with an aggressive N0 tumor and a likelihood of a poor overall survival and a pharmaceutical composition for treating such patients.

US Patent:

20130344062, Dec 26, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/841749

Inventors:

Emanuel Petricoin, III - Gainesville VA, US
Julia Wulfkuhle - Columbia MD, US
Angela Zupa - Potenza, IT

International Classification:

G01N 33/68

US Classification:

4241331, 506 9

Abstract:

This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step of determining if one or more of certain identified proteins are activated in tumor cells obtained from the patient's tumor, wherein the activation of one or more of the proteins indicates that the patient has an aggressive N0 tumor and is likely to have a poor overall-survival. The invention also provides a method for selecting a treatment for an NSCLC patient with an N0 tumor and a method for treating such patients. It further provides a kit for identifying an NSCLC patient with an aggressive N0 tumor and a likelihood of a poor overall survival and a pharmaceutical composition for treating such patients.

US Patent:

59856084, Nov 16, 1999

Filed:

Oct 31, 1997

Appl. No.:

8/962284

Inventors:

Elizabeth J. Luna - Shrewsbury MA
Kersi N. Pestonjamasp - Worcester MA
Robert K. Pope - Worcester MA
Julia D. Wulfkuhle - Shrewsbury MA

Assignee:

University of Massachusetts - Boston MA

International Classification:

C12N 1500

US Classification:

435 691

Abstract:

The invention relates to supervillin polypeptides, nucleic acid molecules encoding supervillin, and uses thereof. Supervillin is related to the actin-binding proteins villin and gelsolin.

US Patent:

20170363630, Dec 21, 2017

Filed:

Dec 8, 2015

Appl. No.:

15/533859

Inventors:

- Fairfax VA, US
Julia WULFKUHLE - Columbia MD, US

International Classification:

G01N 33/574

Abstract:

Disclosed herein are methods for treating subjects with breast cancer, comprising determining a therapeutic regimen for cancer by measuring the level (amount) of proteins of one or more biomarkers. Also disclosed are methods of predicting or assessing therapeutic outcome for subject.

US Patent:

20170160282, Jun 8, 2017

Filed:

Dec 7, 2016

Appl. No.:

15/371975

Inventors:

- Fairfax VA, US
Julia Wulfkuhle - Columbia MD, US

International Classification:

G01N 33/574
A61K 31/4025
A61K 31/454
G01N 33/50
A61K 31/166
A61K 31/5025
A61K 31/496
A61K 31/55
A61K 31/502

Abstract:

Disclosed herein are methods for treating subjects with breast cancer, comprising determining a therapeutic regimen for cancer by measuring the level (amount) of proteins of one or more biomarkers. Also disclosed are methods of treating a subject with breast cancer by predicting or assessing a therapeutic outcome for subject.